Treatment for Outpatient Community-Acquired Pneumonia

Introduction to Treatment Options

The American Thoracic Society and Infectious Diseases Society of America recommend amoxicillin 1 gram orally three times daily as the preferred first-line treatment for healthy outpatients without comorbidities, with doxycycline 100 mg twice daily as an alternative option 1

For healthy patients without comorbidities, the American Thoracic Society and Infectious Diseases Society of America guidelines recommend amoxicillin 1 gram orally three times daily (strong recommendation, moderate quality evidence) 1
Doxycycline 100 mg orally twice daily is an alternative option for healthy patients without comorbidities (conditional recommendation, low quality evidence) 1
Macrolide monotherapy, such as azithromycin or clarithromycin, should only be used if local pneumococcal macrolide resistance is less than 25% (conditional recommendation, moderate quality evidence) 1

For outpatients with comorbidities, combination therapy with a beta-lactam and a macrolide or doxycycline is recommended (strong recommendation, moderate quality evidence) 1
Fluoroquinolone monotherapy, such as levofloxacin or moxifloxacin, is an alternative option for patients with comorbidities (strong recommendation, moderate quality evidence) 1

The American Thoracic Society and Infectious Diseases Society of America recommend against using macrolide monotherapy in areas with more than 25% pneumococcal macrolide resistance (most of the United States) 1
Fluoroquinolones should be avoided in healthy patients without comorbidities to preserve these agents for more complicated cases and prevent resistance development 1
Patients with a history of recent antibiotic exposure should be treated with an alternative antibiotic class due to increased resistance risk 2
Doxycycline can cause photosensitivity reactions, which may limit its use in certain geographic areas or seasons 2

Patients should be reassessed within 3-5 days if no clinical improvement occurs, as this may indicate incorrect diagnosis, resistant pathogens, complications, or need for hospitalization 3
Clinical review at 6 weeks is essential to ensure complete resolution and identify any complications 3

A minimum of 5 days of therapy is required, and treatment should be continued until the patient is afebrile for 48-72 hours with no more than one sign of clinical instability 3